ALTEOGEN Inc. (KOSDAQ:196170)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 21.79T |
| Revenue (ttm) | 202.18B |
| Net Income (ttm) | 125.93B |
| Shares Out | 53.48M |
| EPS (ttm) | 2,262.96 |
| PE Ratio | 180.07 |
| Forward PE | 142.83 |
| Dividend | 371.00 (0.09%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 437,970 |
| Average Volume | 564,237 |
| Open | 399,000 |
| Previous Close | 403,000 |
| Day's Range | 397,000 - 409,500 |
| 52-Week Range | 315,500 - 569,000 |
| Beta | 1.04 |
| RSI | 49.17 |
| Earnings Date | Mar 13, 2026 |
About ALTEOGEN
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]
Financial Performance
Financial StatementsNews
FDA Clears Merck's One-Minute Cancer Shot
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE: MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration i...